查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1850465

代謝體學市場（按成分、適應症、應用和最終用戶分類）—2025-2032 年全球預測

Metabolomics Market by Component, Indication, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年代謝體學市場規模將成長至 73.9 億美元，複合年成長率為 11.68%。

主要市場統計數據
基準年2024年 30.5億美元
預計2025年 33.9億美元
預測年份：2032年 73.9億美元
複合年成長率（%） 11.68%

不斷發展的科學技術正在將代謝體學提升到系統級能力，這將改變生物醫學和環境應用。

隨著研究人員和相關人員尋求更好地理解小分子表現型並探索其應用，代謝體學正受到越來越多的關注。近年來，分析儀器和計算能力的進步使得在複雜生物基質中進行更全面、可重複的代謝物分析成為可能。這些發展重塑了實驗設計，加速了生物標記的發現，並拓寬了代謝體學在藥物開發、臨床研究、環境監測和營養科學的應用範圍。因此，各機構正在重新調整其能力，以將高解析度檢測平台與強大的生物資訊流程相結合。

同時，該領域正從一個以探索為主的領域逐漸成熟，成為一個支持規範決策和臨床效用的領域。對標準化、品管和數據互通性的日益重視，正在推動對整合樣品製備、分離和檢測以及下游資訊學的端到端工作流程的投資。這種整合為縮短週轉時間、提高可重複性和研究間可比性提供了機會。在此背景下，相關人員必須將代謝體學視為一項技術專長，而不僅僅是一項技術專長，而是一項系統級能力，能夠增強治療和環境領域的精準方法。

分析儀器、分離化學和雲端生物資訊學的融合進步正在將代謝體學重塑為一個協作的、以轉化為中心的研究生態系統。

一場變革性轉變正在發生，它將重新定義代謝體學的實踐、資金籌措和商業化方式。在技術水準，質譜儀靈敏度和解析度的提高、核磁共振波譜在無損分析中的廣泛應用，以及新型表面質譜方法，正在擴大代謝物鑑定的可檢測性和可信度。同時，從毛細管電泳到高效液相層析，增強了分離異構體和降低基質效應的能力，從而提高了數據品質和可解釋性。

在數據方面，先進的生物資訊學工具和服務與領域特定資料庫的整合，使得先前極具挑戰性的可擴展註釋和通路映射工作流程成為可能。模組化、雲端生物資訊工具和服務的興起，正在促進跨研究機構的協作分析和可複製的流程。在組織方面，學術研究機構、受託研究機構以及製藥和生物技術公司正在採用混合模式，將內部專業知識與外部服務合作夥伴結合，以加快洞察速度。總而言之，這些轉變正在創造一個更具互通性、以轉化為導向的生態系統，其中方法的嚴謹性、數據透明度和跨部門協作決定了競爭優勢。

不斷變化的美國關稅措施正在促使全球代謝體學企業進行策略性採購調整、供應鏈彈性計畫和合約重組

美國近期的關稅政策正在對全球代謝體學供應鏈產生多方面影響，對籌資策略、供應商選擇和成本結構產生顯著影響。影響進口分析儀器和關鍵零件的關稅可能會改變採購行為，促使實驗室延長儀器生命週期，盡可能優先選擇本地供應商，或尋求其他採購管道。這些行為反應對服務供應商和儀器製造商具有下游影響，他們必須調整分銷策略和客戶支援模式，以保持市場進入和服務連續性。

除了採購之外，關稅主導的變化也會影響合作研究模式。進行跨國計劃的學術和受託研究機構機構在採購專用耗材和替換零件時，可能會面臨更高的行政管理費用和物流複雜性。因此，注重本地生產、區域服務和搶佔式備件庫存的合作夥伴關係更具吸引力。此外，法規合規性和海關相關延誤可能會影響研究時間表，因此需要在計劃設計中製定應急計劃。總而言之，這些動態凸顯了在貿易政策不斷變化的環境下進行代謝體學研究時，供應鏈韌性和積極的合約條款的重要性。

層級細分揭示了組件選擇、呈現優先順序、應用重點和最終用戶需求如何決定代謝體學的最佳工作流程和機會

市場區隔洞察揭示了技術選擇和最終用戶優先順序的交集，從而推動了採用路徑。基於組件，我們將市場細分為生物資訊工具和服務以及代謝體學儀器。生物資訊學提供專用服務而非獨立工具和資料庫，而儀器則細分為檢測技術和分離平台。檢測包括質譜、核磁共振波譜和表面質譜，而分離包括毛細管電泳、氣相層析法、高效液相層析和超高效液相層析。這種以組件為導向的觀點強調，買家通常更重視整合工作流程而非單一產品，他們尋求檢測保真度以及與下游資料處理的兼容性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 將人工智慧和深度學習整合到高通量非靶向代謝體學工作流程中，用於預測性生物標記識別
  • 複雜組織內代謝異質性的單細胞和空間映射在精準醫療應用的進展
  • 開發連接複用阱離子遷移譜質譜平台，以增強代謝組學覆蓋率和結構解析
  • 擴展代謝體學主導的個人化營養平台，利用腸道微生物群代謝分析來實現量身定做的飲食干預
  • 實施結合基因組學、蛋白質組學和轉錄組學的多組體學資料整合框架，進行全面的系統生物學分析
  • 可攜式即時環境電離質譜儀的出現，可用於現場環境和臨床代謝監測

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章代謝體學市場（按成分）

  • 生物資訊學工具和服務
    • 生物資訊服務
    • 生物資訊工具和資料庫
  • 代謝體學儀器
    • 發現工具
      • 質譜法
      • 核磁共振波譜
      • 基於表面的質譜法
    • 隔離工具
      • 毛細管電泳
      • 氣相層析法
      • 高效液相層析
      • 超高效液相層析

第9章代謝體學市場（按適應症）

  • 心血管疾病
  • 代謝紊亂
  • 神經系統疾病
  • 腫瘤疾病

第 10 章代謝體學市場（按應用）

  • 生物標記發現
    • 癌症生物標記
    • 神經系統生物標記
  • 藥物研發
    • 代謝途徑
    • 目標識別
  • 環境科學
    • 農藥殘留分析
    • 水質分析
  • 營養基因體學
    • 心血管健康
    • 肥胖調查
  • 個人化醫療
    • 基因組研究
    • 治療監測
  • 毒性測試

第 11 章代謝體學市場（按最終用戶分類）

  • 學術研究機構
  • 合約研究組織
  • 製藥和生物技術公司

第 12 章代謝體學市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 13 章代謝體學市場：依類別

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國代謝體學市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Afekta Technologies Ltd.
    • BASF SE
    • Bio-Rad Laboratories, Inc.
    • Biocrates Life Science AG
    • Bruker Corporation
    • Clinical Microbiomics A/S
    • Danaher Corporation
    • DNA Xperts Private Limited
    • General Metabolics
    • Hitachi High-Tech Corporation
    • Human Metabolome Technologies Inc.
    • JASCO Corporation
    • Kore Technology Limited
    • LECO Corporation
    • Merck KGaA
    • Metabolon, Inc.
    • Shimadzu Corporation
    • Techcomp Europe Ltd
    • Thermo Fisher Scientific Inc.
    • Waters Corporation
Product Code: MRR-50124643847C

The Metabolomics Market is projected to grow by USD 7.39 billion at a CAGR of 11.68% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.05 billion
Estimated Year [2025] USD 3.39 billion
Forecast Year [2032] USD 7.39 billion
CAGR (%) 11.68%

An evolving scientific and technological landscape is elevating metabolomics into a systems-level capability with transformative implications for biomedical and environmental applications

The metabolomics landscape is experiencing heightened attention as researchers and commercial stakeholders pursue deeper understanding of small-molecule phenotypes and their translational applications. Over recent years, advances in analytical instrumentation and computational capacity have converged to enable more comprehensive, reproducible metabolite profiling across complex biological matrices. These developments are reshaping experimental design, accelerating biomarker discovery, and expanding the practical footprint of metabolomics within drug development, clinical research, environmental monitoring, and nutritional science. As a result, organizations are recalibrating capabilities to integrate high-resolution detection platforms with robust bioinformatics pipelines.

Concurrently, the field is maturing from a predominantly exploratory discipline toward one that supports regulated decision-making and clinical utility. The growing emphasis on standardization, quality control, and data interoperability has prompted investment in end-to-end workflows that join sample preparation, separation and detection, and downstream informatics. This integration creates opportunities for improved turnaround times, reproducibility, and cross-study comparability. Given this context, stakeholders should view metabolomics not simply as a technical specialty but as a systems-level capability that empowers precision approaches across therapeutic and environmental domains.

Converging advances in analytical instrumentation, separation chemistries, and cloud-enabled bioinformatics are reshaping metabolomics into a translationally focused and collaborative ecosystem

Transformative shifts are underway that are redefining how metabolomics is practiced, funded, and commercialized. At the technology level, improvements in mass spectrometry sensitivity and resolution, broader adoption of nuclear magnetic resonance spectroscopy for non-destructive profiling, and novel surface-based mass analysis approaches are expanding the detectability and confidence of metabolite identification. In parallel, the refinement of separation chemistries-ranging from capillary electrophoresis to ultra performance liquid chromatography-has enhanced the ability to resolve isomeric species and reduce matrix effects, thereby enriching data quality and interpretability.

On the data side, the integration of advanced bioinformatics tools and services with domain-specific databases is enabling scalable annotation and pathway mapping workflows that were previously prohibitive. The rise of modular, cloud-enabled bioinformatics tools and services is fostering collaborative analytics and reproducible pipelines across institutions. Organizationally, academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies are adopting hybrid models that blend in-house expertise with external service partners to accelerate time-to-insight. Taken together, these shifts are creating a more interoperable, translationally oriented ecosystem in which methodological rigor, data transparency, and cross-sector collaboration determine competitive advantage.

Evolving United States tariff measures are prompting strategic procurement adaptations, supply chain resilience planning, and contract restructuring across global metabolomics operations

Recent tariff policies originating from the United States have produced a multifaceted set of effects across global metabolomics supply chains, with notable implications for procurement strategies, vendor selection, and cost structures. Tariffs that affect imported analytical instruments and key components can alter purchasing behavior, prompting laboratories to extend equipment lifecycles, prioritize local vendors where feasible, or seek alternative procurement channels. These behavioral responses have downstream consequences for service providers and instrument manufacturers who must adapt distribution strategies and customer support models to maintain market access and service continuity.

Beyond procurement, tariff-driven shifts influence collaboration patterns. Academic research institutes and contract research organizations that operate cross-border projects may encounter increased administrative overhead and logistical complexity when sourcing specialized consumables or replacement parts. As a consequence, partnerships that emphasize local manufacturing, in-region servicing, and pre-emptive spare-part inventories gain attractiveness. Moreover, regulatory compliance and customs-related delays can impact study timelines, necessitating contingency planning in project design. Collectively, these dynamics underscore the importance of supply chain resilience and proactive contractual terms when conducting metabolomics research in an environment shaped by evolving trade policies.

Layered segmentation reveals how component choices, indication priorities, application focus, and end-user needs jointly determine optimal metabolomics workflows and commercial opportunities

Insight into market segmentation clarifies where technology choices and end-user priorities intersect to drive adoption pathways. Based on component, the landscape divides between bioinformatics tools and services and metabolomic instruments; within bioinformatics, offerings span dedicated services and standalone tools and databases, while instruments separate into detection technologies and separation platforms, with detection including mass spectrometry, nuclear magnetic resonance spectroscopy, and surface-based mass analysis and separation encompassing capillary electrophoresis, gas chromatography, high-performance liquid chromatography, and ultra performance liquid chromatography. This component-oriented view highlights that purchasers often evaluate integrated workflows rather than discrete products, seeking compatibility between detection fidelity and downstream data processing.

Based on indication, the workstreams concentrate on cardiovascular disorders, metabolic disorders, neurological disorders, and oncological disorders, each of which places distinct demands on sensitivity, longitudinal sampling, and biomarker validation strategies. Based on application, efforts cluster around biomarker discovery, drug discovery, environmental science, nutrigenomics, personalized medicine, and toxicology testing, with biomarker discovery further differentiating into cancer and neurological biomarker initiatives and drug discovery emphasizing metabolic pathway elucidation and target identification; environmental science applications prioritize pesticide residue and water quality analysis while nutrigenomics focuses on cardiovascular health and obesity research and personalized medicine addresses genomic studies and therapeutic monitoring. Based on end-user, the primary consumers include academic research institutes, contract research organizations, and pharmaceutical and biotechnology companies, and each user group balances different trade-offs between throughput, regulatory readiness, and cost-efficiency. Understanding these layered segmentations enables targeted solution design that aligns analytical capability with clinical or environmental validation requirements.

Distinct regional dynamics across the Americas, Europe Middle East and Africa, and Asia-Pacific create differentiated adoption pathways and partnership strategies for metabolomics stakeholders

Regional dynamics shape technology adoption rhythms, partnership models, and investment priorities across the metabolomics ecosystem. In the Americas, established academic networks and a mature biotechnology industry foster rapid uptake of cutting-edge detection platforms and a strong market for contract research organizations that provide specialized metabolomics services. In contrast, Europe, Middle East & Africa presents a heterogeneous landscape in which centers of excellence coexist with markets prioritizing regulatory harmonization and cross-border collaborative research infrastructures, driving demand for interoperable data platforms and standardized workflows. In the Asia-Pacific region, high growth in life sciences investment, expanding clinical research capacity, and evolving domestic manufacturing capabilities create incentives for both local instrument production and adoption of cloud-enabled bioinformatics services.

These regional patterns influence vendor strategies for product localization, training, and after-sales support. They also affect the design of clinical studies and environmental monitoring programs, as regional regulatory expectations and sampling infrastructures differ. Consequently, organizations must develop adaptive market entry plans that reflect local end-user preferences, talent availability, and distribution networks while leveraging global partnerships to ensure access to specialized detection technologies and advanced informatics.

Competitive differentiation emerges from integrated hardware and software innovation, collaborative validation models, and service-centric approaches that accelerate translational utility

Companies operating in the metabolomics space are differentiating through innovation in detection hardware, enhanced separation chemistries, and integrated bioinformatics services that facilitate end-to-end workflows. Strategic priorities include reducing time-to-result, improving metabolite annotation confidence, and enabling scalable data management across multi-site studies. Market participants are investing in modular platforms that pair high-resolution detection with flexible separation options, thereby allowing customers to tailor analytical approaches to specific indications such as oncology or neurological research. Simultaneously, software providers are emphasizing interoperability, standardized reporting formats, and machine-readable pathway annotations to accelerate translational use.

Partnership models are evolving to emphasize co-development with academic consortia and clinical networks, which expedites the validation of biomarkers and the alignment of analytical protocols with clinical endpoints. Service providers and instrument developers are also placing greater emphasis on training and on-site support offerings to lower barriers to adoption. From an operational standpoint, organizations that maintain robust global service footprints, resilient supply chains, and configurable finance options for capital equipment are better positioned to support diverse customer segments. These strategic orientations collectively shape competitive dynamics and determine which entities can sustainably scale across research and commercial applications.

Adopt integrated product roadmaps, regional service expansion, and collaborative validation frameworks to accelerate adoption and reduce implementation friction across diverse use cases

Industry leaders should prioritize cohesive strategies that bridge instrument performance with analytics and service delivery to maximize value capture. First, aligning product roadmaps so that detection platforms are inherently compatible with separation modules and downstream bioinformatics tools will reduce integration friction for customers and shorten adoption cycles. Second, investing in standardized quality frameworks and interoperable data exports will facilitate multi-site studies and regulatory interactions, thereby increasing credibility for clinical and environmental applications. Third, expanding regional service infrastructures and localized training programs will address end-user needs in the Americas, Europe Middle East & Africa, and Asia-Pacific while mitigating tariff-related supply challenges and logistical delays.

Additionally, organizations should pursue strategic collaborations with academic centers and contract research organizations to validate use cases across cardiovascular, metabolic, neurological, and oncological indications. Companies will benefit from offering modular commercial models that encompass instrument-as-a-service, consumable subscriptions, and bespoke analytics engagements tailored to biomarker discovery, drug discovery, nutrigenomics, personalized medicine, environmental science, and toxicology testing. Finally, enhancing transparency around data provenance and analytical uncertainty will build trust with clinical partners and regulators and will support broader adoption of metabolomics-derived decision tools.

A rigorous mixed-methods approach combining primary stakeholder interviews, technical assessments, and literature synthesis underpins the findings and validates practical implications

This research synthesizes evidence from systematic literature reviews, targeted stakeholder interviews, technical product assessments, and cross-validation of industry-relevant case studies to construct a robust portrait of the metabolomics landscape. Primary research involved structured interviews with laboratory directors, instrumentation specialists, bioinformatics leads, and procurement managers to capture practical constraints and adoption drivers. Secondary research entailed a curated review of peer-reviewed literature, regulatory guidance, patent filings, and technology white papers to validate technical assertions and identify emerging methodological trends.

Analytical approaches included technology readiness assessments, workflow mapping to identify integration bottlenecks, and qualitative triangulation of vendor claims against independent academic evaluations. Data quality protocols emphasized reproducibility checks, expert validation panels, and iterative synthesis to ensure that conclusions reflect both operational realities and scientific rigor. Where appropriate, confidential supplier disclosures and anonymized project data were used to corroborate service delivery models and supportability claims, with findings distilled into actionable implications for practitioners, investors, and policy stakeholders.

A strategic focus on interoperability, validation partnerships, and adaptive commercial models will determine which organizations capture long-term value from metabolomics capabilities

In summary, metabolomics is transitioning into a core capability that supports translational research, regulatory engagement, and environmental monitoring through the convergence of advanced detection technologies, refined separation chemistries, and scalable bioinformatics. This maturation is accompanied by evolving commercial models that emphasize integrated workflows, service delivery, and regional adaptability. Supply chain considerations, including the effects of tariff policy and regional manufacturing trends, add complexity but also create opportunities for differentiated service offerings and local partnerships. Taken together, these forces point to a future in which reproducibility, interoperability, and collaborative validation will determine which organizations lead in delivering metabolomics-driven insights.

For stakeholders, the imperative is clear: invest in interoperable platforms, prioritize partnerships that accelerate clinical validation, and design commercial models that reduce implementation friction for end-users across academic, contract research, and pharmaceutical and biotechnology settings. By doing so, organizations can harness metabolomics to generate robust biological insights that meaningfully inform research, product development, and regulatory decision-making.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence and deep learning in high throughput untargeted metabolomics workflows for predictive biomarker identification
  • 5.2. Advances in single cell and spatial metabolomics mapping metabolic heterogeneity within complex tissues for precision medicine applications
  • 5.3. Development of multiplexed trapped ion mobility spectrometry mass spectrometry platforms for enhanced metabolome coverage and structural elucidation
  • 5.4. Expansion of metabolomics driven personalized nutrition platforms leveraging gut microbiome metabolic profiling for tailored dietary interventions
  • 5.5. Implementation of multi omics data integration frameworks combining metabolomics genomics proteomics and transcriptomics for holistic systems biology analysis
  • 5.6. Emergence of portable and real time ambient ionization mass spectrometry devices for in situ environmental and clinical metabolic monitoring

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Metabolomics Market, by Component

  • 8.1. Bioinformatics Tools & Services
    • 8.1.1. Bioinformatics Services
    • 8.1.2. Bioinformatics Tools & Databases
  • 8.2. Metabolomic Instruments
    • 8.2.1. Detection Tools
      • 8.2.1.1. Mass Spectrometry
      • 8.2.1.2. Nuclear Magnetic Resonance Spectroscopy
      • 8.2.1.3. Surface-based Mass Analysis
    • 8.2.2. Separation Tools
      • 8.2.2.1. Capillary Electrophoresis
      • 8.2.2.2. Gas Chromatography
      • 8.2.2.3. High-Performance Liquid Chromatography
      • 8.2.2.4. Ultra Performance Liquid Chromatography

9. Metabolomics Market, by Indication

  • 9.1. Cardiovascular Disorders
  • 9.2. Metabolic Disorders
  • 9.3. Neurological Disorders
  • 9.4. Oncological Disorders

10. Metabolomics Market, by Application

  • 10.1. Biomarker Discovery
    • 10.1.1. Cancer Biomarkers
    • 10.1.2. Neurological Biomarkers
  • 10.2. Drug Discovery
    • 10.2.1. Metabolic Pathways
    • 10.2.2. Target Identification
  • 10.3. Environmental Science
    • 10.3.1. Pesticide Residue Analysis
    • 10.3.2. Water Quality Analysis
  • 10.4. Nutrigenomics
    • 10.4.1. Cardiovascular Health
    • 10.4.2. Obesity Research
  • 10.5. Personalized Medicine
    • 10.5.1. Genomic Studies
    • 10.5.2. Therapeutic Monitoring
  • 10.6. Toxicology Testing

11. Metabolomics Market, by End-User

  • 11.1. Academic Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical & Biotechnology Companies

12. Metabolomics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Metabolomics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Metabolomics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Afekta Technologies Ltd.
    • 15.3.2. BASF SE
    • 15.3.3. Bio-Rad Laboratories, Inc.
    • 15.3.4. Biocrates Life Science AG
    • 15.3.5. Bruker Corporation
    • 15.3.6. Clinical Microbiomics A/S
    • 15.3.7. Danaher Corporation
    • 15.3.8. DNA Xperts Private Limited
    • 15.3.9. General Metabolics
    • 15.3.10. Hitachi High-Tech Corporation
    • 15.3.11. Human Metabolome Technologies Inc.
    • 15.3.12. JASCO Corporation
    • 15.3.13. Kore Technology Limited
    • 15.3.14. LECO Corporation
    • 15.3.15. Merck KGaA
    • 15.3.16. Metabolon, Inc.
    • 15.3.17. Shimadzu Corporation
    • 15.3.18. Techcomp Europe Ltd
    • 15.3.19. Thermo Fisher Scientific Inc.
    • 15.3.20. Waters Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL METABOLOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL METABOLOMICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS METABOLOMICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA METABOLOMICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL METABOLOMICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL METABOLOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. METABOLOMICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. METABOLOMICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. METABOLOMICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL METABOLOMICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL METABOLOMICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL METABOLOMICS MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & DATABASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & DATABASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & DATABASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & DATABASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & DATABASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & DATABASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL METABOLOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL METABOLOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL METABOLOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL METABOLOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL METABOLOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL METABOLOMICS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL METABOLOMICS MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL METABOLOMICS MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL METABOLOMICS MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL METABOLOMICS MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL METABOLOMICS MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL METABOLOMICS MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL METABOLOMICS MARKET SIZE, BY SURFACE-BASED MASS ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL METABOLOMICS MARKET SIZE, BY SURFACE-BASED MASS ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL METABOLOMICS MARKET SIZE, BY SURFACE-BASED MASS ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL METABOLOMICS MARKET SIZE, BY SURFACE-BASED MASS ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL METABOLOMICS MARKET SIZE, BY SURFACE-BASED MASS ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL METABOLOMICS MARKET SIZE, BY SURFACE-BASED MASS ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL METABOLOMICS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL METABOLOMICS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL METABOLOMICS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL METABOLOMICS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL METABOLOMICS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL METABOLOMICS MARKET SIZE, BY CAPILLARY ELECTROPHORESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL METABOLOMICS MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL METABOLOMICS MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL METABOLOMICS MARKET SIZE, BY GAS CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL METABOLOMICS MARKET SIZE, BY GAS CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL METABOLOMICS MARKET SIZE, BY GAS CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL METABOLOMICS MARKET SIZE, BY GAS CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL METABOLOMICS MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL METABOLOMICS MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL METABOLOMICS MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL METABOLOMICS MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL METABOLOMICS MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL METABOLOMICS MARKET SIZE, BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL METABOLOMICS MARKET SIZE, BY ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL METABOLOMICS MARKET SIZE, BY ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL METABOLOMICS MARKET SIZE, BY ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL METABOLOMICS MARKET SIZE, BY ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL METABOLOMICS MARKET SIZE, BY ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL METABOLOMICS MARKET SIZE, BY ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL METABOLOMICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL METABOLOMICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL METABOLOMICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL METABOLOMICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL METABOLOMICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL METABOLOMICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL METABOLOMICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL METABOLOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL METABOLOMICS MARKET SIZE, BY CANCER BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL METABOLOMICS MARKET SIZE, BY CANCER BIOMARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL METABOLOMICS MARKET SIZE, BY CANCER BIOMARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL METABOLOMICS MARKET SIZE, BY CANCER BIOMARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL METABOLOMICS MARKET SIZE, BY CANCER BIOMARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL METABOLOMICS MARKET SIZE, BY CANCER BIOMARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL BIOMARKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL BIOMARKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL BIOMARKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL BIOMARKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL METABOLOMICS MARKET SIZE, BY NEUROLOGICAL BIOMARKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC PATHWAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC PATHWAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC PATHWAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC PATHWAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC PATHWAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL METABOLOMICS MARKET SIZE, BY METABOLIC PATHWAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL METABOLOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL METABOLOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL METABOLOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL METABOLOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL METABOLOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL METABOLOMICS MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL METABOLOMICS MARKET SIZE, BY PESTICIDE RESIDUE ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL METABOLOMICS MARKET SIZE, BY PESTICIDE RESIDUE ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL METABOLOMICS MARKET SIZE, BY PESTICIDE RESIDUE ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL METABOLOMICS MARKET SIZE, BY PESTICIDE RESIDUE ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL METABOLOMICS MARKET SIZE, BY PESTICIDE RESIDUE ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL METABOLOMICS MARKET SIZE, BY PESTICIDE RESIDUE ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL METABOLOMICS MARKET SIZE, BY WATER QUALITY ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL METABOLOMICS MARKET SIZE, BY WATER QUALITY ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL METABOLOMICS MARKET SIZE, BY WATER QUALITY ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL METABOLOMICS MARKET SIZE, BY WATER QUALITY ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL METABOLOMICS MARKET SIZE, BY WATER QUALITY ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL METABOLOMICS MARKET SIZE, BY WATER QUALITY ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL METABOLOMICS MARKET SIZE, BY CARDIOVASCULAR HEALTH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL METABOLOMICS MARKET SIZE, BY OBESITY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL METABOLOMICS MARKET SIZE, BY OBESITY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL METABOLOMICS MARKET SIZE, BY OBESITY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL METABOLOMICS MARKET SIZE, BY OBESITY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL METABOLOMICS MARKET SIZE, BY OBESITY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL METABOLOMICS MARKET SIZE, BY OBESITY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL METABOLOMICS MARKET SIZE, BY GENOMIC STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL METABOLOMICS MARKET SIZE, BY GENOMIC STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL METABOLOMICS MARKET SIZE, BY GENOMIC STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL METABOLOMICS MARKET SIZE, BY GENOMIC STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL METABOLOMICS MARKET SIZE, BY GENOMIC STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL METABOLOMICS MARKET SIZE, BY GENOMIC STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL METABOLOMICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL METABOLOMICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL METABOLOMICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL METABOLOMICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL METABOLOMICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL METABOLOMICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL METABOLOMICS MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL METABOLOMICS MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL METABOLOMICS MARKET SIZE, BY TOXICOLOGY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL METABOLOMICS MARKET SIZE, BY TOXICOLOGY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL METABOLOMICS MARKET SIZE, BY TOXICOLOGY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL METABOLOMICS MARKET SIZE, BY TOXICOLOGY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL METABOLOMICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL METABOLOMICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL METABOLOMICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL METABOLOMICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL METABOLOMICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL METABOLOMICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL METABOLOMICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL METABOLOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL METABOLOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL METABOLOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL METABOLOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL METABOLOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL METABOLOMICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL METABOLOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL METABOLOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL METABOLOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL METABOLOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL METABOLOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL METABOLOMICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL METABOLOMICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL METABOLOMICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS METABOLOMICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS METABOLOMICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS METABOLOMICS MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS METABOLOMICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS METABOLOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS METABOLOMICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS METABOLOMICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA METABOLOMICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA METABOLOMICS MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA METABOLOMICS MARKET SIZE, BY ENVIRONMENTAL SCIENCE, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA METABOLOMICS MARKET SIZE, BY NUTRIGENOMICS, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA METABOLOMICS MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA METABOLOMICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA METABOLOMICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA METABOLOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA METABOLOMICS MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA METABOLOMICS MARKET SIZE, BY BIOINFORMATICS TOOLS & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA METABOLOMICS MARKET SIZE, BY METABOLOMIC INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA METABOLOMICS MARKET SIZE, BY DETECTION TOOLS, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA METABOLOMICS MARKET SIZE, BY SEPARATION TOOLS, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA METABOLOMICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA METABOLOMICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA METABOLOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA METABOLOMICS MARKET SIZE, BY BIOMARKER DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA METABOLOMICS MARKET SIZE, BY D